Stock listing
Stockholm:ALVOSDB Alvotech Aktie
Swedish listing (Stockholm) of Alvotech · home listing NASDAQ:ALVO
Follow Alvotech into a list and get an email when it puts out news.
Share price · OMXSTO:ALVO_SDB
43.60 SEK -2.95 (-6.3%)
Close on Nov 20, 2026
- Day range
- 43.15 – 46.55 SEKNov 20, 2026
- Volume
- 15,855 sharesNov 20, 2026
- Market cap
- 15.56B SEKAt the close on Nov 20, 2026 · price × 356.8M shares outstanding
- 52-week range
- 27.50 – 64.90 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 2.83M SEKMedian day 31,654 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALVO · Home | $4.12 USD | -0.43 (-9.5%) | 826,571 | $4.26 | $4.29 | $4.09 | $4.55 | Close on Nov 20, 2026 |
| Frankfurt:Z45 | €3.67 EUR | -0.17 (-4.4%) | — | €3.68 | €3.69 | €3.67 | €3.84 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OMXSTO:ALVO_SDB · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 47.70 | +1.70 | +3.7% | 45.00 | 48.50 | 45.00 | 14,372 | |
| 46.00 | +1.65 | +3.7% | 44.35 | 48.20 | 44.35 | 54,366 | |
| 44.35 | -1.75 | -3.8% | 46.00 | 46.40 | 43.80 | 12,667 | |
| 46.10 | +0.15 | +0.3% | 46.00 | 46.45 | 44.20 | 25,053 | |
| 45.95 | -2.05 | -4.3% | 48.00 | 48.00 | 45.15 | 31,654 | |
| 48.00 | -1.10 | -2.2% | 48.15 | 48.65 | 47.65 | 5,798 | |
| 49.10 | -0.15 | -0.3% | 49.25 | 49.60 | 47.15 | 13,704 | |
| 49.25 | +3.00 | +6.5% | 46.30 | 49.25 | 45.55 | 11,454 | |
| 46.25 | +0.70 | +1.5% | 45.55 | 46.50 | 45.55 | 29,137 | |
| 45.55 | -0.50 | -1.1% | 46.05 | 47.60 | 45.25 | 26,588 | |
| 46.05 | -3.15 | -6.4% | 49.75 | 50.90 | 46.05 | 39,458 | |
| 49.20 | -1.90 | -3.7% | 51.10 | 51.20 | 49.20 | 23,101 | |
| 51.10 | -0.50 | -1.0% | 53.50 | 53.50 | 50.90 | 12,336 | |
| 51.60 | +1.50 | +3.0% | 49.45 | 54.80 | 49.45 | 97,905 | |
| 50.10 | -0.10 | -0.2% | 50.20 | 51.50 | 49.35 | 15,729 | |
| 50.20 | -2.00 | -3.8% | 52.20 | 53.30 | 50.20 | 18,943 | |
| 52.20 | -0.60 | -1.1% | 53.00 | 53.70 | 50.90 | 26,263 | |
| 52.80 | +0.10 | +0.2% | 52.30 | 56.10 | 52.30 | 13,765 | |
| 52.70 | -3.50 | -6.2% | 56.20 | 56.20 | 52.70 | 12,237 | |
| 56.20 | 0.00 | 0.0% | 57.20 | 59.40 | 56.20 | 9,391 | |
| 56.20 | +0.20 | +0.4% | 56.00 | 57.60 | 55.90 | 19,594 | |
| 56.00 | -3.10 | -5.2% | 58.20 | 59.50 | 56.00 | 24,572 | |
| 59.10 | -0.10 | -0.2% | 61.00 | 61.00 | 58.80 | 45,651 | |
| 59.20 | -1.80 | -3.0% | 61.80 | 61.90 | 59.00 | 105,463 | |
| 61.00 | +5.80 | +10.5% | 55.20 | 64.90 | 55.20 | 107,958 | |
| 55.20 | -0.30 | -0.5% | 56.00 | 57.00 | 55.10 | 15,792 | |
| 55.50 | -2.40 | -4.1% | 58.80 | 59.00 | 55.00 | 39,093 | |
| 57.90 | -3.20 | -5.2% | 62.00 | 62.50 | 57.90 | 375,288 | |
| 61.10 | +2.30 | +3.9% | 60.10 | 61.70 | 59.50 | 34,995 | |
| 58.80 | +0.20 | +0.3% | 58.60 | 60.10 | 55.00 | 48,037 | |
| 58.60 | +1.20 | +2.1% | 58.30 | 59.50 | 57.50 | 24,683 | |
| 57.40 | +0.80 | +1.4% | 58.00 | 58.70 | 55.60 | 64,577 | |
| 56.60 | 0.00 | 0.0% | 58.00 | 59.50 | 56.60 | 28,152 | |
| 56.60 | +0.40 | +0.7% | 57.50 | 59.80 | 56.50 | 36,306 | |
| 56.20 | +2.30 | +4.3% | 55.60 | 59.10 | 55.60 | 52,570 | |
| 53.90 | +1.70 | +3.3% | 52.20 | 55.20 | 52.20 | 26,205 | |
| 52.20 | -1.20 | -2.2% | 53.50 | 54.50 | 50.90 | 38,868 | |
| 53.40 | +4.95 | +10.2% | 48.25 | 53.70 | 48.25 | 57,040 | |
| 48.45 | -1.15 | -2.3% | 50.40 | 51.40 | 47.85 | 340,464 | |
| 49.60 | -2.20 | -4.2% | 51.90 | 52.70 | 49.05 | 25,760 | |
| 51.80 | +1.80 | +3.6% | 50.90 | 52.20 | 50.80 | 369,476 | |
| 50.00 | +1.55 | +3.2% | 49.15 | 50.90 | 49.10 | 3,960 | |
| 48.45 | -1.75 | -3.5% | 51.30 | 52.00 | 48.35 | 18,275 | |
| 50.20 | +0.10 | +0.2% | 49.15 | 51.50 | 49.15 | 37,822 | |
| 50.10 | +0.20 | +0.4% | 51.50 | 52.00 | 49.90 | 19,912 | |
| 49.90 | +0.30 | +0.6% | 50.30 | 51.50 | 49.60 | 37,204 | |
| 49.60 | -0.60 | -1.2% | 50.00 | 51.50 | 49.60 | 44,848 | |
| 50.20 | +1.30 | +2.7% | 48.90 | 50.50 | 47.80 | 35,257 | |
| 48.90 | +0.20 | +0.4% | 49.00 | 49.40 | 47.60 | 96,424 | |
| 48.70 | +2.70 | +5.9% | 46.50 | 49.60 | 46.00 | 85,754 | |
| 46.00 | -0.10 | -0.2% | 46.10 | 47.00 | 45.10 | 27,985 | |
| 46.10 | -0.35 | -0.8% | 46.45 | 47.80 | 45.00 | 20,854 | |
| 46.45 | -3.20 | -6.4% | 49.50 | 49.50 | 45.95 | 35,034 | |
| 49.65 | +0.65 | +1.3% | 49.70 | 51.20 | 47.85 | 77,192 | |
| 49.00 | +7.45 | +17.9% | 41.55 | 49.70 | 41.50 | 72,747 | |
| 41.55 | +0.75 | +1.8% | 40.00 | 45.05 | 38.10 | 73,965 | |
| 40.80 | +3.25 | +8.7% | 37.00 | 40.80 | 36.05 | 37,163 |
- Ticker
- Stockholm:ALVO_SDB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Nov 11, 2026
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
Latest earnings call · Nov 12, 2026
Alvotech (NASDAQ:ALVO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
9M 2026 Earnings Presentation
Earnings · 31 slides
Latest news
Alvotech to Present at Upcoming Investor Conferences in November
Nov 2, 2026
Closed 45.95 (-4.3%) on Nov 2, 2026
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Oct 28, 2026
Closed 49.25 (+6.5%) on Oct 28, 2026
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
Oct 20, 2026
Closed 51.60 (+3.0%) on Oct 20, 2026
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Oct 14, 2026
Closed 52.80 (+0.2%) on Oct 14, 2026
Alvotech: Half yearly financial audit reports reviews 2026 10 07 13h09m51 (1)
Oct 12, 2026
Closed 52.70 (-6.2%) on Oct 13, 2026
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Oct 6, 2026
Closed 59.10 (-0.2%) on Oct 7, 2026
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Oct 5, 2026
Closed 61.00 (+10.5%) on Oct 5, 2026
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
Aug 31, 2026
Closed 48.70 (+5.9%) on Aug 31, 2026
Alvotech to present at upcoming investor conferences in September
Aug 27, 2026
Closed 46.10 (-0.8%) on Aug 27, 2026
Alvotech on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 49 in the last 12 months · 224 in all · newest Nov 11, 2026 · oldest 2022
- Calls
- 18 calls with a replay · 18 with a transcript · latest Nov 12, 2026
- Decks
- 12 decks · latest Nov 12, 2026
Where Alvotech is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALVO · Home listing | NASDAQ | United States | USD |
| OMXICE:ALVO | OMXICE | Iceland | ISK |
| Stockholm:ALVOSDB · This page | Stockholm | Sweden | SEK |
| LS Exchange:A3DK8U | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DK8U | Lang & Schwarz | Germany | EUR |
| gettex:Z45 | gettex | Germany | EUR |
| Frankfurt:Z450 | Frankfurt | Germany | EUR |
| BX Swiss:ALVO | BX Swiss | Switzerland | CHF |
| BOATS:ALVO | BOATS | United States | USD |
| Dusseldorf:Z450 | Dusseldorf | Germany | EUR |
| Frankfurt:Z45 | Frankfurt | Germany | EUR |
| Munich:Z45 | Munich | Germany | EUR |
| Stuttgart:Z45 | Stuttgart | Germany | EUR |
| BX Swiss:ALVOUSD | BX Swiss | Switzerland | USD |
| Dusseldorf:Z45 | Dusseldorf | Germany | EUR |
| Hamburg:Z45 | Hamburg | Germany | EUR |
| Turquoise:ALVOS | Turquoise | United Kingdom | SEK |
Valuation
EV/sales 5.7× against a median of 15.5×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.78B USD
- P/E
- Loss
- EV/sales
- 5.7×
- EV/EBITDA
- 31.4×
- Price/book
- Negative equity
- Gross margin
- 60.5%
- Operating margin
- 9.6%
- Net margin
- −36.5%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX | US$1.53B | US$987.7M | n/a | 14.5× | n/a | 1.7× | −697.1% | 0.0× | 2.83 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.42B | US$1.14B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| Median of the others | US$1.44B | US$1.24B | 15.5× | 2.7× | −205.1% | 0.1× | 1.70 |
Forecasts
3 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.036 · 4 analysts
- Revenue, year to Dec 2026
- 652.3M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Lisa Graver | Chief Executive Officer |
| Linda Jónsdóttir | Chief Financial Officer |
| Joseph E. McClellan | Chief Operating Officer |
| Benedikt Stefansson | VP Investor Relations and Global Communications IS |
| MediaBenedikt Stefansson | VP Investor Relations and Global CommunicationsSarah Macleod, Head of Global |
| Patrik Ling | VP of Investor Relations Scandinavia |
| Kathryn Gunnarsson | SVP Global Talent & People Experience |
| Anthony M. Maffia | Chief Quality and Regulatory Affairs Officer |
| Balaji Prasad | Chief Strategy Officer |
| Neha Patel | Chief Information Officer |
| Robert Wessman | Executive Chairman |
Board
| Director | Role |
|---|---|
| Robert Wessman | Executive Chairman |
Events
Calls
| Call | When | Status |
|---|---|---|
| Alvotech (NASDAQ:ALVO) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2026 Earnings Call | Thu, Aug 20, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2025 Earnings Call | Thu, Mar 19, 2026 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2024 Earnings Call | Fri, Aug 16, 2024 · 8:00 AM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| Alvotech (NASDAQ:ALVO) Q1 2024 Earnings Call | Wed, May 22, 2024 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2023 Earnings Call | Thu, Mar 21, 2024 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2023 Earnings Call | Wed, Nov 29, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2023 Earnings Call | Thu, Aug 31, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q1 2023 Earnings Call | Fri, May 19, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q4 2022 Earnings Call | Thu, Mar 02, 2023 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q3 2022 Earnings Call | Wed, Nov 16, 2022 · 8:00 AM ET | Replay |
| Alvotech (NASDAQ:ALVO) Q2 2022 Earnings Call | Thu, Sep 01, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 11, 2026 · After close | −5.1% |
| Q2 2026 | Aug 19, 2026 · After close | +7.0% |
| Q1 2026 | May 5, 2026 · After close | +2.0% |
| Q4 2025 | Mar 18, 2026 | −6.3% |
| Q3 2025 | Nov 12, 2025 · After close | −1.4% |
| Q2 2025 | Aug 13, 2025 · After close | −5.4% |
| Q1 2025 | May 7, 2025 | +17.7% |
| Q4 2024 | Mar 26, 2025 · After close | −10.3% |
| Q3 2024 | Nov 13, 2024 · After close | +1.2% |
| Q2 2024 | Aug 15, 2024 · After close | +8.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 21, 2024 · After close | +0.4% |
| Q4 2023 | Mar 20, 2024 · After close | −1.1% |
| Q3 2023 | Nov 28, 2023 · After close | −4.1% |
| Q2 2023 | Aug 30, 2023 · After close | +1.8% |
| Q1 2023 | May 19, 2023 · Before open | +0.6% |
| Q4 2022 | Mar 1, 2023 · After close | +0.8% |
| Q3 2022 | Nov 15, 2022 · After close | +4.3% |
| Q2 2022 | Aug 31, 2022 · After close | −14.3% |
| Q1 2022 | May 16, 2022 · After close | 0.0% |
| Q4 2021 | Mar 30, 2022 · After close | +0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 9M 2026 Earnings Presentation | Earnings | 31 slides | Nov 12, 2026 |
| H1 2026 Earnings Presentation | Earnings | 31 slides | Aug 20, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 7, 2026 |
| FY2025 Earnings Presentation | Earnings | 19 slides | Mar 19, 2026 |
| FY2025 Earnings Presentation | Earnings | 36 slides | Mar 19, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 23 slides | Nov 13, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 12 slides | Aug 14, 2025 |
| SPAC Merger (May 2022) | SPAC merger | 80 slides | May 17, 2022 |
| Oaktree Acquisition Corp. II — SPAC Merger (March 2022) | SPAC merger | 84 slides | Mar 23, 2022 |
| SPAC Merger (March 2022) | SPAC merger | 84 slides | Mar 23, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SPAC Merger (February 2022) | SPAC merger | 64 slides | Feb 15, 2022 |
| SPAC Merger (December 2021) | SPAC merger | 62 slides | Dec 7, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Public offering of ordinary shares Closed: US$98M raised · US$3.75 a share · BofA Securities +2 Dealers: BofA Securities (co-lead), Jefferies (co-lead), Evercore ISI (co-lead) Use of proceeds: Continued development of biosimilar assets, working capital and general corporate purposes | Jun 18, 2026 | |
| Private placement of ordinary shares Announced: about US$67M · US$3.75 a share Use of proceeds: Continued development of biosimilar assets, working capital and general corporate purposes | Jun 18, 2026 | |
| Senior unsecured convertible bonds due 2030 Made bigger: US$108M · DNB Carnegie Dealers: DNB Carnegie (lead) Use of proceeds: Continued investment in the R&D pipeline, scaling up production and global product launches. | Dec 17, 2025 | |
| Private placement of sDRs and ordinary shares Closed: DNB Carnegie Investment Bank AB (publ) +3 Dealers: DNB Carnegie Investment Bank AB (publ) (co-lead), Citigroup Global Markets Limited (co-lead), Skandinaviska Enskilda Banken AB (publ) (co-lead), ACRO Securities HF (co-lead) Use of proceeds: Accelerate R&D activities, especially in Sweden after the Xbrane R&D acquisition, expand pipeline, and general corporate purposes | Jun 11, 2025 | |
| Public offering of swedish Depository Receipts (SDRs) Update: about SEK 39M · SEK 87.51 a receipt · DNB Markets, a part of DNB Bank ASA, Sweden Branch +2 Dealers: DNB Markets, a part of DNB Bank ASA, Sweden Branch, Carnegie Investment Bank, DNB Carnegie Investment Bank AB (publ) | May 19, 2025 | US$3.99M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 586.3M | 489.7M | 91.4M | 83.0M | 36.8M | 66.6M | 31.9M |
| Cost of revenue | 235.6M | 185.3M | 160.9M | 64.1M | 0 | 0 | |
| Gross profit | 350.8M | 304.4M | -69.4M | 18.9M | 36.8M | 66.6M | 31.9M |
| Research and development | 184.2M | 171.3M | 210.8M | 180.6M | 191.0M | 148.1M | 95.6M |
| Selling, general and administrative | 90.9M | 61.5M | 73.0M | 186.7M | 84.1M | 58.9M | 48.6M |
| Operating income | 78.2M | 69.6M | -354.9M | -346.4M | -235.5M | -137.5M | -61.4M |
| Depreciation and amortization | 37.9M | 31.3M | 24.2M | 20.4M | 18.2M | 16.4M | 14.6M |
| EBITDA | 116.1M | 100.9M | -330.6M | -326.0M | -217.3M | -121.1M | -46.8M |
| Interest expense | 149.2M | 303.2M | 267.2M | 188.4M | 117.4M | 161.6M | 95.8M |
| Income before tax | 136.3M | -217.6M | -651.0M | -551.6M | -149.2M | -291.8M | -209.4M |
| Income tax | 108.4M | 14.3M | -99.3M | -38.1M | -47.7M | -121.7M | 491.0K |
| Net income | 27.9M | -231.9M | -551.7M | -513.6M | -101.5M | -170.0M | -209.9M |
| Earnings per share, basic | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 | -1.82 | -0.86 |
| Earnings per share, diluted | 0.10 | -0.87 | -2.43 | -2.60 | -0.92 | -1.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 172.4M | 51.4M | 11.2M | 66.4M | 17.6M | 31.7M | |
| Receivables | 69.7M | 160.2M | 41.3M | 33.0M | 29.4M | 33.1M | |
| Inventory | 220.1M | 127.9M | 74.4M | 71.5M | 39.1M | 9.65M | |
| Current assets | 574.0M | 455.0M | 194.8M | 230.7M | 119.8M | 86.2M | |
| Property, plant and equipment | 356.4M | 284.5M | 236.8M | 220.6M | 78.5M | 177.0M | |
| Goodwill | 12.8M | 11.3M | 12.1M | 11.6M | 12.4M | 13.4M | |
| Total assets | 1.49B | 1.22B | 950.1M | 828.4M | 598.0M | 474.4M | |
| Accounts payable | 126.1M | 67.1M | 80.6M | 49.2M | 28.6M | 12.0M | |
| Current liabilities | 304.1M | 193.4M | 260.9M | 167.3M | 111.8M | 51.0M | |
| Long-term debt | 1.26B | 1.04B | 922.1M | 744.7M | 398.1M | 565.4M | |
| Total debt | 1.30B | 1.07B | 960.2M | 764.6M | 400.9M | 567.9M | |
| Total liabilities | 1.77B | 1.63B | 1.88B | 1.39B | 733.6M | 1.34B | |
| Shareholders' equity | -284.5M | -412.8M | -932.5M | -564.4M | -135.6M | -867.2M | |
| Shares outstanding | 312.0M | 301.8M | 266.8M | 252.2M | 893.1K | 31.3M | 243.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -50.2M | -236.8M | -312.2M | -312.4M | -228.2M | -74.3M | -88.5M |
| Capital spending | -64.5M | -53.7M | -33.2M | -37.9M | -20.5M | -7.49M | -8.05M |
| Free cash flow | -114.7M | -290.5M | -345.4M | -350.3M | -248.6M | -81.8M | -96.6M |
| Cash from investing | -104.2M | -18.9M | -46.3M | -63.5M | -40.6M | -16.9M | -12.9M |
| Cash from financing | 270.8M | 297.3M | 301.3M | 424.9M | 254.8M | 55.4M | 116.4M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | |
| Share buybacks | -9.80M | ||||||
| Change in cash | 116.4M | 41.6M | -57.2M | 49.0M | -14.0M | -35.8M | 15.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 14, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 29, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 304 filings. Open Filings
Cap table
Built by 6ix from Alvotech’s releases · as of Jun 18, 2026
- Common shares
- 356,817,038
- Fully diluted
- 356,817,038
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 356,817,038 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 356,817,038 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| ALVOTECHBenedikt Stefansson | VP Investor Relations and Global · Oct 6, 2025 – Nov 5, 2026 · Past |
| Anthony M. Maffia | Chief Quality and Regulatory Affairs Officer · Since at least Mar 18, 2026 |
| Balaji V. Prasad | Chief Strategy Officer · Since at least Mar 27, 2025 |
| Benedikt Stefansson | VP Investor Relations and Global Communications IS · Since at least Dec 31, 2025 |
| CommunicationsBenedikt Stefansson | VP Global Communications and Investor · Sep 19, 2025 – Nov 5, 2026 · Past |
| Joseph E. McClellan | Chief Operating Officer · Since at least Oct 20, 2026 |
| Kathryn Gunnarsson | SVP Global Talent & People Experience · Since at least Nov 5, 2026 |
| Linda Jónsdóttir | Chief Financial Officer · Since at least Jul 10, 2025 |
| Lisa Graver | Chief Executive Officer · Since at least Jan 6, 2026 |
| MediaBenedikt Stefansson | VP Investor Relations and Global CommunicationsSarah Macleod, Head of Global · Since at least Dec 31, 2025 |
All 13 people
| Person | Seat |
|---|---|
| Neha Patel | Chief Information Officer · Since at least Nov 5, 2026 |
| Patrik Ling | VP of Investor Relations Scandinavia · Since at least Aug 20, 2025 |
| Robert Wessman | Executive Chairman · Since at least Nov 2, 2026 |
Log in to ask 6ix AI your own questions about Alvotech.